RecruitingPhase 2NCT06670352

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients with Primary IgAN

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Enrollment

80 participants

Start Date

Oct 12, 2024

Study Type

INTERVENTIONAL

Conditions

IgA Nephropathy (IgAN)

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HSK39297 100mgBID, a drug called HSK39297 200mgQD, and others for people with iga nephropathy (igan). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.